|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
2013
|
|
gptkbp:ATCCode
|
N06AX26
|
|
gptkbp:availableOn
|
gptkb:tablet
|
|
gptkbp:brand
|
gptkb:Brintellix
gptkb:Trintellix
|
|
gptkbp:CASNumber
|
508233-74-7
|
|
gptkbp:category
|
serotonin reuptake inhibitors
serotonin receptor modulators
|
|
gptkbp:chemicalFormula
|
C18H22N2S
|
|
gptkbp:contraindication
|
hypersensitivity to vortioxetine
|
|
gptkbp:developedBy
|
gptkb:Takeda
gptkb:Lundbeck
|
|
gptkbp:eliminationHalfLife
|
66 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vortioxetine
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
serotonin modulator and stimulator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:Lundbeck
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young adults and children)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
dizziness
sexual dysfunction
|
|
gptkbp:synonym
|
Lu AA21004
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Brintellix
gptkb:Trintellix
|
|
gptkbp:bfsLayer
|
7
|